Skip to main content
Contact Us
Subscribe
E-Edition
84°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
ZyVersa Therapeutics, Inc. - Common Stock
(NQ:
ZVSA
)
3.850
UNCHANGED
Streaming Delayed Price
Updated: 3:56 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ZyVersa Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Why Is ZyVersa Therapeutics (ZVSA) Stock Up 37% Today?
February 26, 2024
ZyVersa Therapeutics stock is rising higher on Monday as shares of ZVDA experience heavy pre-market trading this morning.
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
February 26, 2024
We're starting the trading week with a breakdown of the biggest pre-market stock movers traders need to know about on Monday morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
February 23, 2024
Via
Benzinga
ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases
February 14, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Why ZyVersa Therapeutics Shares Are Down 40%
December 07, 2023
ZyVersa Therapeutics Inc (NASDAQ: ZVSA) shares are trading lower by 43.7% to $1.20 Thursday morning.
Via
Benzinga
ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option
February 22, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
February 09, 2024
Via
Benzinga
ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones
February 07, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes
January 31, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer’s Disease
January 24, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
January 18, 2024
Via
Benzinga
Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
January 18, 2024
Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourth-quarter financial results. Revenues of $1.538 billion, down 19.0% Y/Y, slightly topped the...
Via
Benzinga
Why Is Inflammatory Disease-Focused ZyVersa Therapeutics Stock Trading Higher Today?
January 17, 2024
ZyVersa reveals study in Acta Neuropathologica Communications. Learn how inhibiting NLRP3 inflammasome with Inflammasome ASC Inhibitor IC 100 prevents TNBC brain metastasis.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
January 17, 2024
Via
Benzinga
ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis
January 17, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on Benzinga All Access
January 10, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets
January 04, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024
January 03, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
This Biotech Is Targeting Indications Worth $70 Billion
December 22, 2023
Stephen C. Glover, Co-founder, Chairman, CEO and President of ZyVersa Therapeutics Inc. (NASDAQ: ZVSA) was recently a guest on Benzinga’s All-Access.
Via
Benzinga
Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
December 19, 2023
Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy...
Via
Benzinga
Why Motus GI Holdings Shares Are Trading Lower By Around 46%; Here Are 20 Stocks Moving Premarket
December 19, 2023
Shares of Motus GI Holdings, Inc. (NASDAQ: MOTS) shares fell sharply in pre-market trading after the company priced its $5 million public offering. Motus GI Holdings shares dipped 46.5% to $1.15 in...
Via
Benzinga
ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2024”
December 18, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200
December 14, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Dow Surges 100 Points; Ciena Posts Upbeat Earnings
December 07, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 100 points on Thursday. The Dow traded up 0.28% to 36,155 while the NASDAQ rose 1.41% to 14,346.47. The S&P...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Methode Electronics Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
December 07, 2023
Shares of Methode Electronics, Inc (NYSE: MEI) fell sharply during Thursday’s session following weak quarterly earnings.
Via
Benzinga
Gold Moves Lower; Dollar General Earnings Beat Estimates
December 07, 2023
U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining around 100 points on Thursday. The Dow traded up 0.06% to 36,077.32 while the NASDAQ rose 1.09% to 14,301.04....
Via
Benzinga
Topics
Earnings
Stocks
Exposures
Financial
US Equities
ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes
December 07, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Nasdaq Jumps Over 100 Points; US Jobless Claims Edge Higher
December 07, 2023
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.04% to 36,068.53 while the...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Rivian (RIVN) Stock Just Scored a New ‘Buy’ Rating
December 07, 2023
Rivian stock is gaining on Thursday after Stifel weighed in on RIVN shares with a buy rating and set a price target of $25 per share.
Via
InvestorPlace
Why Is ZyVersa Therapeutics (ZVSA) Stock Down 44% Today?
December 07, 2023
ZyVersa Therapeutics stock is falling hard on Thursday after the company priced a public offering for shares of ZVSA this morning.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.